Literature DB >> 3037036

Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents.

S K Jacobs, C W Parham, B Holcomb, B Ikejiri, P L Kornblith, E A Grimm.   

Abstract

The killing of human glioma by lymphokine activated killer (LAK) cells was studied. LAK cells generated by culturing recombinant interleukin-2 (IL-2) with human peripheral blood lymphocytes (PBL) obtained from normal volunteers markedly lysed allogeneic glioma grown in tissue culture. Susceptibility of glioma to lysis by LAK cells was abrogated by pretreating the glioma cells with trypsin or chymotrypsin, but was unaffected by pretreatment with hydrocortisone, neuraminidase, glycosidases or sodium periodate. These results suggest that the cell surface determinant on human glioma cells responsible for its tumor selective lysis by LAK is a protein sensitive to trypsin and chymotrypsin.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3037036     DOI： 10.1007/BF00162760

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  17 in total

1.  Kinetics of the induction of DNA synthesis in lymphocytes by periodate.

Authors:  A Ravid; A Novogrodsky
Journal:  Exp Cell Res       Date:  1976-01       Impact factor: 3.905

2.  The T antigen of guinea-pig and human red cells.

Authors:  F M BURNET; S G ANDERSON
Journal:  Aust J Exp Biol Med Sci       Date:  1947-09

3.  Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.

Authors:  M Aymard-Henry; M T Coleman; W R Dowdle; W G Laver; G C Schild; R G Webster
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

4.  Biophysical properties of cultured human glial cells.

Authors:  M C Trachtenberg; P L Kornblith; J Häuptli
Journal:  Brain Res       Date:  1972-03-24       Impact factor: 3.252

5.  Blocking of CTL-mediated killing by monoclonal antibodies to LFA-1 and Lyt-2, 3. II. Evidence that trypsin pretreatment of target cells removes a non-H-2 molecule important in killing.

Authors:  S H Gromkowski; W Heagy; E Martz
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

7.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  2 in total

Review 1.  Prioritization schema for immunotherapy clinical trials in glioblastoma.

Authors:  Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

2.  Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Authors:  Seok-Gu Kang; Chung Hun Ryu; Sin Soo Jeun; Chun Kun Park; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2004-02-13       Impact factor: 1.475
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.